Persistence with prescribed antimuscarinic therapy for overactive bladder: A UK experience

BJU International

Volumn 110, Issue 11, 2012, Pages 1767-1774

  Wagg, Adrian ^a   Compion, Gerhard ^b   Fahey, Amanda ^c   Siddiqui, Emad ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Astellas Pharma Europe   (United Kingdom)

^c Astellas Pharma UK   (United Kingdom)

Author keywords

antimuscarinic drugs; overactive bladder; persistence; solifenacin

Indexed keywords

DARIFENACIN; FLAVOXATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED RELEASE FORMULATION; HUMAN; MAJOR CLINICAL STUDY; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; UNITED KINGDOM;

EID: 84870912754     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11023.x     Document Type: Article

References (47)

1. Gulur DM, Drake MJ,. Management of overactive bladder. Nat Rev Urol 2010; 7: 572-82
2. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P,. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009; 28: 287
3. Haab F, Castro-Diaz D,. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 2005; 59: 931-7
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al,. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
5. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ,. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
6. European Association of Urology. EAU guidelines on urinary incontinence. 2009. EAU 2011. Available at: http://www.uroweb.org/gls/pdf/ Urinary%20Incontinence%202010.pdf. Accessed January 2011
7. Ouslander JG,. Management of overactive bladder. N Engl J Med 2004; 350: 786-99
8. Brown JS, McGhan WF, Chokroverty S,. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (Suppl.): S574-9
9. McGhan WF,. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001; 7 (Suppl.): S62-75
10. Smith AL, Wein AJ,. Recent advances in management of bladder overactivity. F1000 Med Rep 2010; 2: 9 (doi:10.3410/M2-9)
11. Chapple CR,. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl.): 33-46
12. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J,. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; (4): CD003781
13. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R,. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006; 97: 540-6
14. Siami P, Seidman LS, Lama D,. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002; 24: 616-28
15. Haab F, Cardozo L, Chapple C, Ridder AM,. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84
16. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R,. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008; 14: 291-301
17. Cramer JA, Roy A, Burrell A, et al,. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7
18. Hill MN, Miller NH, DeGeest S,. ASH position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich) 2010; 12: 757-64
19. Krueger KP, Berger BA, Felkey B,. Medication adherence and persistence: a comprehensive review. Adv Ther 2005; 22: 313-56
20. Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L,. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care 2009; 15 (Suppl.): S118-22
21. Yu YF, Nichol MB, Yu AP, Ahn J,. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 2005; 8: 495-505
22. World Health Organization. Adherence to long-term therapies: evidencefor action. 2003. WHO 2003 January 20; Available at: http://www.who.int/chp/ knowledge/publications/adherence-report/en/index.html. Accessed January 2011
23. New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease. 2009. NEHI 2011; Available at: http://www.nehi.net/uploads/full-report/ pa-issue-brief-final.pdf. Accessed March 2011
24. Basra RK, Wagg A, Chapple C, et al,. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008; 102: 774-9
25. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z,. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005; 11 (Suppl.): S121-9
26. Sears CL, Lewis C, Noel K, Albright TS, Fischer JR,. Overactive bladder medication adherence when medication is free to patients. J Urol 2010; 183: 1077-81
27. Mullins CD, Subak LL,. New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs. Am J Manag Care 2005; 11 (Suppl.): S101-2
28. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM,. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95: 81-5
29. Ioannidis JP, Lau J,. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-43
30. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S,. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988-93
31. Brubaker L, Fanning K, Goldberg EL, et al,. Predictors of discontinuing overactive bladder medications. BJU Int 2010; 105: 1283-90
32. Sexton CC, Notte SM, Maroulis C, et al,. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011; 65: 567-85
33. Brostrom S, Hallas J,. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009; 65: 309-14
34. Linner L, Schioler H, Samuelsson E, Milsom I, Nilsson F,. Low persistence of anticholinergic drug use in Sweden. Eur J Clin Pharmacol 2011; 67: 535-6
35. Tosteson AN, Grove MR, Hammond CS, et al,. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115: 209-16
36. Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C,. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010; 21: 145-55
37. Huybrechts KF, Ishak KJ, Caro JJ,. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38: 922-8
38. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M,. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114-7
39. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB,. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15: 728-40
40. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al,. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093-100
41. Benner JS, Nichol MB, Rovner ES, et al,. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010; 105: 1276-82
42. NICE implementation uptake report: drugs used in the management of urinary incontinence: NICE clinical guideline 40 (sub-section 1.2.6 drug therapies, NICE, London 2008). 1-7
43. Blok B, Van Kerrebroeck P, Buijs S, De Vried C,. Persistence with antimuscarinics in a European study of patients with overactive bladder syndrome. IUGA Meeting, Lago di Como, Italy, 16-20 June 2009. 2009. Abstract
44. Kraus SR, Ruiz-Cerda JL, Martire D, Wang JT, Wagg AS,. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76: 1350-7
45. Castro-Diaz D, Miranda P, Sanchez-Ballester F, Arumi D, Lizarraga I, Ebel Bitoun C,. Why OAB treatment change is so common? 'IMPACTA' study to evaluate reasons for treatment change. ICS/IUGA 2010, Toronto. 2010. Abstract
46. Siddiqui E, Wood D, Compion G,. A comprehensive Patient Support Programme improves persistence with solifenacin in overactive bladder (OAB). 2010. p. UP-2.41
47. Cooper A, Drake J, Brankin E,. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60: 896-905